Does extra height justify a higher risk of breast cancer?
While there are no firm data with respect to its oncogenic potential in the human breast, increasing evidence of the mitogenic activity of IGF on breast tissue at the time of puberty suggests caution in the use of recombinant growth hormone in the treatment of short prepubertal girls. This applies to those without evidence of classic growth hormone deficiency, particularly in the presence of a family history of breast cancer.
Stoll
B A
BA
Oncology Department, St. Thomas' Hospital, London, England.
D000293:Adolescent; D000328:Adult; D001827:Body Height / Q000502:physiology*; D001846:Bone Development / Q000502:physiology; D001943:Breast Neoplasms / Q000453:epidemiology / Q000209:etiology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006133:Growth Substances / Q000502:physiology; D006801:Humans; D015994:Incidence; D012307:Risk Factors
D006133:Growth Substances